Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN
February 11, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTCQB: KLFE) (“Kannalife” or the “Company”), a biopharmaceutical company specializing in the research and development of...
Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead
January 28, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife, Inc. Issues Update on Intellectual Property and Patent Estate
January 22, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain
January 14, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Penn., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine™
January 07, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife, Inc. Announces Filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders
December 11, 2019 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol “KLFE”
December 09, 2019 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife, Inc. to Present Breakthrough CIPN Study Findings on the Comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference
June 27, 2019 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTC: KLFE) (“Kannalife” or “the Company”), a biopharmaceutical company focused on the research, development and discovery of...
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
May 21, 2019 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and...
Kannalife Spokesman Nick Lowery Wins 2018 CNBC Stock Draft
February 05, 2019 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce and congratulate the Company’s...